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Abstract
Immunity to severe malaria is the first level of immunity acquired to Plasmodium falciparum. Antibodies to the variant
antigen PfEMP1 (P. falciparum erythrocyte membrane protein 1) present at the surface of the parasitized red blood cell
(pRBC) confer protection by blocking microvascular sequestration. Here we have generated antibodies to peptide
sequences of subdomain 2 of PfEMP1-DBL1a previously identified to be associated with severe or mild malaria. A set of sera
generated to the amino acid sequence KLQTLTLHQVREYWWALNRKEVWKA, containing the motif ALNRKE, stained the live
pRBC. 50% of parasites tested (7/14) were positive both in flow cytometry and immunofluorescence assays with live pRBCs
including both laboratory strains and in vitro adapted clinical isolates. Antibodies that reacted selectively with the sequence
REYWWALNRKEVWKA in a 15-mer peptide array of DBL1a-domains were also found to react with the pRBC surface. By
utilizing a peptide array to map the binding properties of the elicited anti-DBL1a antibodies, the amino acids WxxNRx were
found essential for antibody binding. Complementary experiments using 135 degenerate RDSM peptide sequences
obtained from 93 Ugandan patient-isolates showed that antibody binding occurred when the amino acids WxLNRKE/D
were present in the peptide. The data suggests that the ALNRKE sequence motif, associated with severe malaria, induces
strain-transcending antibodies that react with the pRBC surface.
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Introduction
The protozoan parasite Plasmodium falciparum infects some 225
million people annually and causes the death of < 1 million
individuals, mainly children under the age of five and pregnant
women [1]. In order to establish persistent blood stage infections,
P. falciparum undergoes antigenic variation. The major variant
antigen PfEMP1 (P. falciparum erythrocyte membrane protein 1) is
expressed at the red blood cell (RBC) surface and is encoded by
the var gene family with around 60 copies per haploid genome
[2,3,4]. PfEMP1 is a virulence associated adhesion molecule that
participates in the causation of severe malaria by mediating the
accumulation of parasitized- and unparasitized erythrocytes in the
microvasculature through endothelial binding (cytoadhesion) and
through binding to unparasitized erythrocytes (rosetting) [5]. The
NTS-DBL1a domain of PfEMP1 has been identified both as a
ligand for rosetting and cytoadhesion involving receptors such as
heparan sulfate, complement receptor 1 and blood group A
[6,7,8].
Acquired immunity to malaria develops in individuals living in
endemic areas, after recurrent exposure to the parasite, but it is
not sterilising [9,10,11]. Likewise, women become resistant to
pregnancy-associated malaria after repeated pregnancies and
infections but the presence of scanty low-grade parasitaemia is
also seen in the immune [12,13]. Immunity to severe disease is the
first level of protection that develops in endemic areas and it is
associated with the presence of antibodies to variable surface
antigens such as PfEMP1 at the parasitized red blood cell (pRBC)
surface [14,15,16,17]. Such antibodies confer protection by
preventing the sequestration of pRBC (rosetting and cytoadher-
ence) and by opsonizing pRBCs for phagocytosis [12,18,19,20,21].
It is not understood how immunity to the highly variable
PfEMP1 antigen develops. There are two main hypotheses: one
suggests that immunity consists of strain-transcending, cross-
reactive antibodies to a few highly conserved epitopes whereas the
other implies that immunity is comprised of a large pool of more
strain-specific antibodies. Early indications that immunity is strain-
specific came from studies on malaria infection as a treatment for
neurosyphilis [22], and there are also studies using in vitro adapted
laboratory P. falciparum strains, that indicate antibodies to PfEMP1
to react in a strain-specific manner [18,20]. However, clinical data
suggest that patients rapidly acquire immunity that protects
against severe disease [14,15,16,17] and varying degrees of cross-
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reactivity have been demonstrated on a serological level using
either sera from malaria infected individuals on heterologous
parasites or sera from PfEMP1-immunized animals on heterolo-
gous PfEMP1 proteins or parasites [23,24,25,26,27,28,29].
By studying the var gene transcription profiles of fresh clinical
P. falciparum isolates of 93 Ugandan children we have previously
demonstrated a correlation between different degenerate PfEMP1-
DBL1a amino acid motifs and different states of malaria [30]. The
collected sequences were examined with a novel method of region
alignment of homology areas (MOTIFF) to identify degenerate
sequence motifs correlated with specific disease states. The key
DBL1a motifs identified were found also expressed in in vitro
adapted strains. We hypothesized that subgroups of cross-reactive
PfEMP1-DBL1a sequences are exposed on the pRBC surface and
are recognized by the immune system leading to the development
of cross-reactive antibodies that protect against severe malaria. In
this paper we show that the earlier identified sequence motifs can
induce antibodies and that some of them react with the surface of
the live pRBC of different parasite isolates as well as in vitro
adapted strains in a strain-transcendent fashion.
Results
Generation of Specific Antibodies Towards NTS-DBL1a
Sequence Motifs
A set of peptides covering six of the degenerate PfEMP1
sequence motifs that were associated with severe or mild malaria
in clinical isolates from Uganda [30] were produced (Table 1, Fig.
S1 and S2). Of the six peptides, four were from motifs associated
with severe malaria and two were from motifs associated with mild
malaria. The peptide sequences and the corresponding parasite
isolate expressing the particular motif are listed in Table 1. Two
rabbits and one rat were immunized per peptide. All of the six
DBL1a -motif peptides induced antibodies in both species as
confirmed in ELISA with the corresponding peptide (not shown).
After an initial screen on live pRBCs using flow cytometry (FACS)
and immunofluorescence assays (IFA) on air-dried monolayers of
pRBCs, a subset of six sera (rabbit 1 and 2 for DBL1a-S1S2;
rabbit 2 and rat for DBL1a-RDSM; rabbit 1 and rat for DBL1a-
L1M4) showing positive results were affinity purified on the
corresponding peptide using the Ultralink Iodoacetyl matrix (see
Material and Methods).
Immunofluorescence Assay on Air-dried Monolayers of
pRBC
All affinity purified peptide antibodies were assayed on air-dried
monolayers for binding to pRBCs from a panel of Ugandan
parasites and laboratory strains. IgG from the rabbit immunized
with the DBL1a-RDSM (respiratory distress severe malaria)
peptide showed a donut shape fluorescence pattern (Fig. 1A),
typical for exported proteins like PfEMP1 associated with
Maurer’s clefts in the red blood cell cytosol [31]. The rabbit
anti-DBL1a-RDSM IgG showed the same pattern for all parasite
strains and isolates screened (UAS22, FCR3S1.2, R29, UAS29,
3D7AH1 and UKS111, Fig. S3). The rat immunized with the
DBL1a-RDSM peptide (Fig. 1A) as well as the other affinity
purified antibodies showed reactivity with the internal parasite
only.
Recognition of pRBC Surface Exposed Epitopes by Anti-
DBL1a Motif Antibodies
The surface reactivity of the set of six anti-peptide antibodies
was analyzed using FACS. Most antibody-preparations were
negative in FACS, including rabbit anti-DBL1a-RDSM antibod-
ies, but rat anti-DBL1a-RDSM antibodies stained the surface of
pRBCs parasitized with the UAS22 parasite strain (the homolo-
gous parasite from which the RDSM peptide sequence was
obtained; Fig. 1B). In live cell fluorescence microscopy, these
antibodies showed a dotty fluorescence pattern (Fig. 1C), typical
for PfEMP1-staining of the parasitized erythrocyte surface
[20,28,32]. To further explore the reactivity of the anti-DBL1a
motif antibodies, a panel of seven recently established isolates from
Ugandan children and seven long term propagated strains
(Tables 2 and 3) were screened in FACS and in live cell IFA.
The rat anti-DBL1a-RDSM antibodies showed surface reactivity
both in FACS and in live cell IFA with seven out of 14 parasites
studied, (Fig. 1D). Four parasites, UKS111, UAS29, 3D7AH1 and
3D7var4 reacted moderately while three parasites, UAS22, R29
and UAM51, showed stronger surface reactivity than the others.
The latter three parasites are all shown to express a PfEMP1 with
a DBL1a domain containing an amino acid motif similar to that
used for immunization. Figure 2A shows the correlation between
the surface reactivity in FACS and the demonstrated amino acids
in the RDSM sequence of the screened parasite strains and
isolates. Figure 2B depicts the RDSM peptide location within a
NTS-DBL1a model of the parasite strain R29 based on the
crystallized NTS-DBL1a-domain of the Palo AltovarO parasite
line.
Immunogenicity of the RDSM Peptide
We further explored the immunogenicity of the RDSM peptide
by immunizing another set of six rats. Five immunizations were
carried out and all animals showed reactivity in FACS after the
third immunization (Fig. 3). This relatively strong reactivity
Table 1. Synthesized peptides.
Motifa Motif name Peptide sequenceb Expressed in parasite
EPGIQHLEK S1S2 HLRHEPGIQHLEKRLESMFQNIQN UAS22
ALNRKE RDSMc (S3) KLQTLTLHQVREYWWALNRKEVWKA UAS22
TCGATM/FSKNI H1H2 ITCGATMNDIFSKNIR UAS22
NDEVWK H3 TDNDEVWKGLRAVFGKI UAS31
ICTVL M5 SNICTVLARSFADIGDIV UAS29
DSIKKY L1/M4 EGDSIKKYHDKHQGT UAS29
aIdentified by Normark et al [30].
bThe motifs are underlined in the peptide sequences.
cThe motif is named RDSM (Respiratory distress severe malaria) in this article to avoid confusion with the S3 domain of DBL1a [35].
doi:10.1371/journal.pone.0052679.t001
Strain-Transcending Antibodies to PfEMP1
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Figure 1. The DBL1a-RDSM peptide induces strain-transcending antibodies that react with the pRBC surface. A. Indirect IFA on air-
dried monolayers of the clinical isolate UAS22. Specific donut pattern shown with rabbit anti-DBL1a-RDSM IgG (green) while rat anti-DBL1a-RDSM
IgG only stained the internal parasite. The parasite nucleus is stained with DAPI (blue). The rat anti-DBL1a-RDSM IgG is from rat 1. B. Analysis of
surface recognition by FACS. Rat anti-DBL1a-RDSM IgG (red) assayed on the parasites UAS22 and FCR3S1.2. Non-immune rat IgG at the same
concentration is shown in blue. The rat anti-DBL1a-RDSM IgG is from rat 1. C. Live cell immunofluorescence microscopy. Rat anti-DBL1a-RDSM IgG
binding to UAS22. The parasite nucleus is stained with ethidium bromide (red). The rat anti-DBL1a-RDSM IgG is from rat 1. D. Analysis of surface
recognition by FACS and live cell immunofluorescence in 14 isolates and strains with rat anti-DBL1a-RDSM IgG. The adjusted MFI ratio 6 SEM is
shown. The corresponding results for immunofluorescence assays (IFA) on live parasites are also shown.
doi:10.1371/journal.pone.0052679.g001
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Figure 2. RDSM amino acid sequence and location within the PfEMP1-DBL1a domain. A. Surface recognition correlated with DBL1a-RDSM
amino acid sequence. Only strains and isolates with known or predicted (by RT-PCR) DBL1a amino acid sequence are included. B. Location of the
RDSM peptide within the predicted crystal structure of the R29 PfEMP1-DBL1a domain. The blue part depicts the RDSM peptide and the red part the
RDSM motif. The R29 sequence is modeled on the crystallized Palo AltovarO NTS-DBL1a.
doi:10.1371/journal.pone.0052679.g002
Table 2. Clinical isolates included in the study.
Clinical isolate Sex Age (months) Clinical diagnosis
Initial rosetting
rate (%)
In vitro rosetting
rate (%) Parasite generations at FACS/IFAd
UAS22 M 17 Respiratory distress 47 ,5 20–24
UAS29 F 12 Respiratory distress 9 10 14–18
UAS31 M 30 Severe malaria NUD 56 20 10–14
UKS111 F 30 Cerebral malaria 50 40 1–4
UKM62 M 15 Mild malaria ,5 ,5 9–10
UAM15 M 24 Mild malaria 2 ,5 15–18
UAM51 F 6 Mild malaria 4 ,5 15–18
dDominant var gene determined by reverse transcriptase-PCR at zero generations for UAS22, UAS29, UAS31, UAM15 and UAM 51 as published in Normark et al [30].
doi:10.1371/journal.pone.0052679.t002
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decreased with subsequent immunizations but after the last
immunization, five out of six rat sera (named rat sera 2–7 with
rat 1 being the rat immunized with the RDSM peptide in the first
round of immunizations) showed reactivity in ELISA with the
corresponding peptide (data not shown). Sera from rat 4 and 7 also
showed reactivity in FACS (Fig. 3, S4A and S4B).
Peptide Array Reveals Specific Antibody Recognition
In order to map the antibody binding of the anti-DBL1a-
RDSM IgG in detail, specific peptide arrays holding overlapping
15-mer peptides were produced as in [33]. The arrays hold five
NTS-DBL1a domains from long-term cultivated parasites
(FCR3S1.2var1, FCR3S1.2var2, R29, Palo AltovarO, 3D7var4) and
shorter DBL1a tags from three Ugandan isolates (UAS22, UAS29
and UAS31) (see Table S1A and B). The peptide array confirmed
a correlation between antibody recognition in the RDSM area of
DBL1a in the array and antibody reactivity in FACS. Rat anti-
DBL1a-RDSM IgG reacted on the microarray with peptides
corresponding to the parasites that were positive in FACS (Fig. 4A,
4B and S5) while there was no reactivity with the peptides in the
NTS-DBL1a sequences from the parasites that were negative in
FACS. The rabbit anti-DBL1a-RDSM IgG also showed reactivity
in the same area; however the recognition pattern was somewhat
different (Fig. 4A, 4B and S6) reacting also with FCR3S1.2.
Alanine Walking Identifies Essential Amino Acids for
Antibody Binding
In order to map the antibody binding and specificity in detail,
alanine replacement peptide arrays were produced, i.e. peptide
arrays with individual alanine point mutations covering the
reacting RDSM area of five DBL1a sequences (FCR3S1.2var1,
FCR3S1.2var2, R29, Palo AltovarO, UAS22; Table S1C). For the
rat anti-DBL1a-RDSM IgG, the most important amino acid in
the UAS22 sequence was an asparagine (N) in the middle of the
motif sequence (REYWWALNRKEVWKA) (Fig. 5). For the R29
sequence, two additional amino acids were important for binding
of the rat anti-DBL1a-RDSM IgG, namely the arginine (R) in the
motif sequence as well as one tryptophan (W) located adjacent to
the motif (REYWWALNRKEVWKA) (Fig. 5). The binding
recognition profiles of the anti-DBL1a-RDSM rat sera number
4 and 7 were also analyzed with the alanine replacement arrays
which showed a similar recognition pattern with an asparagine
being important for antibody binding (REYWWALNR-
KEVWKA) (Fig. S7). However other residues also seem central
for antibody binding in the UAS22 sequence including tryptophan
and leucin residues (REYWWALNRKEVWKA) for both sera. In
the R29 sequence, in addition to the centrally placed asparagine,
tryptophans on both sides of the motif as well as a lysine
(REYWWALNRKEVWKA) were important for antibody bind-
ing.
For rabbit anti-DBL1a-RDSM IgG the reactivity diminished in
a number of peptide sequences from UAS22 and R29 (Fig. 6).
However the most important amino acids seem to be located at the
end of the UAS22 sequence, with amino acids glutamic acid,
valine and tryptophan (EVW) being important for antibody
binding (REYWWALNRKEVWKA). For the R29 sequence,
alanine replacement of the tryptophan at the end of the sequence
completely abolished the binding of the rabbit anti-DBL1a-
RDSM IgG.
Cross-reactivity with Different 15-mers of the RDSM
Degenerate Motif Sequence
The cross-reactive potential of the rat anti-DBL1a-RDSM IgG
was explored using a third peptide array with 15-mer peptides of
all identified unique sequences in the RDSM area from the
Ugandan material (Table S1D) [30]. Of the 241 sequences
Table 3. Laboratory strains included in the study.
Laboratory strain Rosetting rate (%) Selection/enrichment
FCR3S1.2 .80 mAb enrichment
FCR3S1.6 ,5 –
R29 70 mAb enrichment
HB3 0 –
3D7AH1 ,5 –
3D7var4 ,5 mAb enrichment
NF54CSA ,5 CSA panning
doi:10.1371/journal.pone.0052679.t003
Figure 3. Surface reactivity of anti-DBL1a-RDSM rat sera to pRBCs of UAS22. FACS results from sera after third immunization assayed on
UAS22 in trophozoite stage. For comparison, serum from rat 1 (fourth immunization) is included as a reference. The adjusted MFI ratio 6 SEM is
shown.
doi:10.1371/journal.pone.0052679.g003
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included in the Ugandan study, 135 were unique sequences and 47
showed reactivity with the anti-DBL1a-RDSM IgG, albeit at
different degrees. As seen in Fig. 7, high reactivity was seen with
peptide sequences containing leucin, lysine and aspartic or
glutamic acid (ALNRKE/D). This amino acid composition
gradually diminished in conjunction with lower antibody recog-
nition. In the sequences showing medium reactivity with the rat
anti-DBL1a-RDSM IgG, aspartic acid was replaced by glutamic
acid to some degree (ALNRKE). In the sequences with low or no
reactivity, leucin was replaced by an alanine and the positively
charged lysine was replaced by the negatively charged aspartic or
glutamic acid (TANRE/D). In addition, the aspartic or glutamic
acid were replaced by threonine or glutamine (TANRET/Q). No
correlation between the recognition patterns of the rat anti-
DBL1a-RDSM IgG and the rabbit anti-DBL1a-RDSM IgG was
found (Fig. S8).
Discussion
It is not fully understood how protective immunity to
P. falciparum malaria is acquired. Antibodies to the variant surface
antigen PfEMP1 are part of this immunity but the exact location of
the antibody binding sites in this multi-domain variant protein
remains unknown. Herein we show that a linear sequence motif
(ALNRKE) present in the subdomain 2 (SD2) of PfEMP1-DBL1a
from a Ugandan isolate (UAS22) can induce surface reactive
antibody responses. The anti-DBL1a-RDSM antibodies display
live cell surface reactivity with seven out of 14 parasites tested,
both laboratory strains and in vitro adapted clinical isolates of early
generations, suggesting that the identified PfEMP1-DBL1a
sequence motif is available at the pRBC surface. Similarly, dot
blots performed with the rat anti-DBL1a-RDSM antibodies to
recombinant proteins of NTS-DBL1a-domains from
FCR3S1.2var1, FCR3S1.2var2, R29 and Palo AltovarO showed
reactivity with the R29 protein but not for the other included
proteins that lack the motif (data not shown). This is in
concordance with the FACS and the live cell IFA data. We
further utilized a peptide array to map the binding properties of
the elicited anti-DBL1a-RDSM antibodies and the amino acids
WxxNRx were found essential for antibody binding. In comple-
mentary experiments using 135 degenerate RDSM peptide-
sequences obtained from 93 Ugandan patient-isolates we found
that antibody binding occurred predominantly when the amino
acids WxLNRKE/D were present in the peptide. The data
suggest that the identified epitope in SD2 could be a target for the
induction of strain-transcending antibodies. These antibodies
could be involved in opsonisation and phagocytosis but not in
the disruption of rosettes since none of the obtained antibodies
disrupted rosettes in any of the included parasite strains or clinical
isolates (data not shown). However rosette disruption has been
shown with antibodies to the loop of the flanking subdomain 3
(SD3) [34]. In a recent study, Ghumra et al [28] describe surface
reactive antibodies with strain-transcending activity. Some of these
Figure 4. Peptide array mapping the rabbit and rat anti-DBL1a-RDSM IgG binding. The amino acid sequences are read from N- to C-
terminal. The amino acids included in the RDSM peptide are shown in bold letters. Statistically significant changes comparing immune IgG and non-
immune IgG are marked with an asterisk * P,0.05. The rat anti-DBL1a-RDSM IgG is from rat 1. A. DBL1a domain from UAS22. The rabbit/rat anti-
DBL1a-RDSM IgG is shown in black and the non-immune IgG is shown in grey. B. DBL1a domain from R29. The rabbit/rat anti-DBL1a-RDSM IgG is
shown in black and the non-immune IgG is shown in grey.
doi:10.1371/journal.pone.0052679.g004
Strain-Transcending Antibodies to PfEMP1
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e52679
antibodies did not have rosette inhibiting effect and one could
speculate that the ALNRKE-sequence could be one of the
epitopes important for the strain-transcending activity shown in
the study. The RDSM motif is present in the homology block 5
(HB5) which is suggested to be frequently exposed on the surface
of PfEMP1 [35]. HB5 is one of the most prevalent homology
blocks and is present in nearly all DBL domains [35]. No
correlation was found between the RDSM motif and the different
PfEMP1 domain cassettes recently reported to be associated with
severe malaria [36,37,38,39].
Figure 5. Alanine replacement peptide array of the DBL1a domains of parasites UAS22 and R29. Rat anti-DBL1a-RDSM IgG is depicted in
black and reactivity to the wild type (WT) sequence is shown in grey as a reference. The reactivity is shown as a ratio between modified and WT
sequence. Statistically significant changes compared to WT sequence are marked with an asterisk. * P,0.05.
doi:10.1371/journal.pone.0052679.g005
Strain-Transcending Antibodies to PfEMP1
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Figure 6. Alanine replacement peptide array of the DBL1a domains of parasites UAS22 and R29. Rabbit anti-DBL1a-RDSM IgG is
depicted in black and reactivity to the WT sequence is shown in grey as a reference. The reactivity is shown as a ratio between modified and WT
sequence. Statistically significant changes compared to WT sequence are marked with an asterisk. * P,0.05.
doi:10.1371/journal.pone.0052679.g006
Strain-Transcending Antibodies to PfEMP1
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The RDSM peptide that includes both the motif (ALNRKE)
and surrounding amino acids (Table 1) was used to immunize both
rabbits and rats, but only rats induced surface reactive antibodies.
A peptide array with alanine point mutations in the RDSM
sequence revealed that amino acids important for binding vary to
some extent between different parasite sequences. Still an
asparagine (N), an arginine (R) as well as a leucin (L) and a lysine
(K) (ALNRKEVW) seem to be important for binding of the rat
anti-DBL1a-RDSM antibodies. In contrast, for the rabbit anti-
DBL1a-RDSM antibodies (that were negative in FACS) the most
important amino acids seem to be glutamic acid (E), valine (V) and
tryptophan (W) (ALNRKEVW), at the C-terminus of the
sequence, just outside the RDSM motif. Indeed, the two amino
acids (VW) in this area of the DBL1a-domain are conserved in a
broad range of DBL1a sequences from different geographical
locations. The two amino acids are situated just upstream of the
PoLV3 motif [40] and are commonly used as an anchor when
aligning DBL1a-domains. This pattern of conservation might be
the reason why the rabbit anti-DBL1a-RDSM antibodies reacted
with all tested parasite strains and isolates on dried monolayers of
pRBC but not at the surface of the pRBC. On air-dried
monolayers, the RBC membrane is disrupted and the antibodies
are able to detect antigens inside the cell. One could speculate that
the valine and tryptophan are exposed during the export of the
PfEMP1 in the pRBC cytosol but are hidden upon exposure of the
protein at the surface of the pRBC.
When the rat anti-DBL1a-RDSM IgG were assayed on a
peptide array with 135 unique sequence-combinations of the
RDSM peptide, high antibody recognition was shown in peptide
sequences containing leucin, lysine and aspartic or glutamic acid
as part of the motif (ALNRKD/E). In the sequences with no
reactivity, leucin was replaced by an alanine and the positively
charged lysine replaced by the negatively charged aspartic or
glutamic acid (TANRE/D). Interestingly, Dahlba¨ck et al have
characterized a motif in the same location as the RDSM motif in
the DBL3X domain of the pregnancy associated PfEMP1,
VAR2CSA [41]. In placental isolates from Senegalese women,
the EIEKD motif was associated with parasites from primi-
gravidae and the motif GIEGE and G/EIERE with parasites from
multi-gravidae. Comparing the three motifs there is a replacement
from a lysine (EIEKD) in the motif associated with parasites from
primi-gravidae to an arginine or glycine (EIERE, GIEGE) in the
motifs associated with parasites from multi-gravidae. This
correlates with the findings herein. Preliminary data from our
group indicate that there is reactivity to the ALNRKE-peptide
with human sera from Cameroon (data not shown), however
background reactivity with non-immune human IgG to the same
area in the peptide array was also seen to various degrees (Albrecht
et al, manuscript in preparation).
The sequence motifs used for peptide design in this study are all
located in putative loops or a-helical semi-variable sequences of
SD2 flanking subdomains 1 and 3 (SD1, SD3) the latter which are
probably involved in mediating receptor binding of DBL1a
[34,42]. The hypervariable parts of the domain are unlikely to take
part in any interaction due to the high sequence variability. The
identified DBL1a-RDSM motif could be a linear epitope since it is
both recognized on the peptide array as well as on the surface of
the live pRBC which is similar to findings with Plasmodium vivax for
the P. vivax Duffy binding protein (PvDBP) [43]. Mapping of
naturally acquired antibodies, that prevented binding of PvDBP to
reticulocytes, identified linear epitopes in the DBL domain of
PvDBP which were mainly localized in SD2 [43]. The DBL
domain of PvDBP (called RII-PvDBP) is similar in sequence and
structure to other DBL domains of Plasmodium parasites including
the DBL1a domain of PfEMP1. Batchelor et al show in a recent
paper that PvDBP binds its receptor, DARC, via a receptor
mediated dimerization [44]. The dimer interface is formed by the
two SD2s of the DBL domains and the dimeric organization is
crucial for receptor binding, creating a positively charged binding
pocket for DARC. The authors suggest this model to be applicable
to receptor recognition by other DBL domain-containing proteins
such as PfEMP1 and PfEBA-175. Interestingly, the DBL1a-
RDSM motif is situated in the SD2 of DBL1a and is close to the
predicted binding pocket of PvDBP. However, as discussed before,
none of the anti-DBL1a-RDSM antibodies showed rosette
disrupting capacity. Preliminary data indicate that the epitopes
important for rosetting are situated in SD3 and SD1 in the
DBL1a-domain [34,42].
The DBL1a-RDSM motif seems to be immunogenic since all
seven rats immunized generated antibodies that showed surface
reactivity with the live pRBC during the immunization schedule
but the antibody reactivity was down-regulated upon repeated
immunizations. Further, reactivity was seen for pre-immune sera
of some animals in the peptide array. This may suggest that
animals at least in-part are tolerized to the epitope and therefore
diminish reactivity. A limited immunogenicity has also been seen
with some HIV epitopes e.g. the monomeric CD4-binding site of
gp120 as well as for epitopes of the surface glycoprotein
haemagglutinin (HA) of influenza viruses [45].
In conclusion, this paper suggests that the identified PfEMP1-
DBL1a-RDSM sequence is available at the parasitized erythrocyte
surface of different clinical isolates and laboratory strains and that
this motif can induce antibodies. In order to develop an anti-severe
malaria vaccine much work is needed to identify the immunogens
that can induce broad reactivity and functional antibodies that can
confer protection by blocking sequestration and by opsonizing
pRBCs for phagocytosis. Our results are a step forward to
understand the basis of anti-plasmodial immune responses in order
to identify the types of immunity required for a malaria vaccine
that targets PfEMP1 at the surface of the pRBC.
Materials and Methods
Ethics Statement
Collection of human samples was conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from the patients or their legal
guardians. The study was approved by Karolinska Institutet’s
Regional Ethical Review Board (permission 03/095) and the
Uganda National Council for Science and Technology (permission
MV717). Animal immunizations were carried out by Agrisera
(Umea˚, Sweden) and were approved by Umea˚ Ethical Review
Board (permissions A88-08 and A89-08). All animal work followed
the Swedish Law and Regulations (1988:534 and L55).
Parasite Lines, Cultivation and Dominant Var Genes
A total of 14 P. falciparum isolates, strains or clones were used in
this study. Of these, seven were clinical isolates: UAS22, UAS29,
Figure 7. Antibody cross-reactivity to 135 unique RDSM peptide sequences. Rat anti-DBL1a-RDSM IgG recognition of 135 peptides
covering the RDSM sequence motif. Degenerate motifs associated with different antibody recognition are shown to the left. Red letters indicates high
reactivity, orange medium reactivity, green low reactivity and blue no reactivity.
doi:10.1371/journal.pone.0052679.g007
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UAS31, UKS111, UAM15, UAM51, UKM62 collected in
Uganda in 2002 and 2003 [30]. Patients were recruited in two
locations in Uganda: at the district hospital in Apac, which is
situated in a malaria holoendemic area [46] 250 km north of
Kampala, and at the Mulago hospital, located in Kampala. In
addition seven laboratory strains or clones from different
geographical locations were used in the study including
FCR3S1.2, FCR3S1.6, 3D7AH1, 3D7var4, HB3, NF54CSA
and R29. For details of the included isolates and strains, see
Tables 2 and 3. All 14 parasites were cultivated using standard
methods developed by Trager and Jensen [47,48] with the
modifications that all in vitro adapted Ugandan isolates were
cultivated in a gas mixture of 90% NO2, 5% O2 and 5% CO2 and
by shaking the flasks as described [49]. Parasites were kept
synchronous by intermittently treating the cultures with 5%
sorbitol (w/v). The parasitemia was counted and the rosetting rate
was determined by calculating the number of trophozoite pRBCs
within rosettes, relative to the total number of trophozoite pRBCs
present in the culture. A rosette was defined as at least two
unparasitized RBCs bound to one pRBC. The rosetting rate was
maintained with Ficoll enrichment as previously described [48].
FCR3S1.2 and R29 enrichment was carried out monthly with
monoclonal antibodies (mAb) to the dominant PfEMP1 (IT4var60
and IT4var9 respectively) as described earlier [50,51]. The
3D7var4 strain was a kind gift from Louise Joergensen, University
of Copenhagen, Denmark and was similarly enriched on mAbs
[52]. All experiments on FCR3S1.2, R29 and 3D7var4 were
carried out within two weeks after mAb enrichment.
The dominantly expressed var genes for the clinical isolates
UAS22, UAS29, UAS31, UAM15, UAM51 have been deter-
mined earlier [30]. In the paper by Normark et al, trophozoite
stages parasites were used and var genes were amplified by reverse
transcriptase-PCR with degenerate primers nDBLf (TKGCAGC-
MAAWTAYGARGX), nDBLr (KTCCACCAATCTTCYCT), a-
AF (GCACGMAGTTTTGC) and a-BR (GCCCATTCSTC-
GAACCA), known to amplify ,90% of var genes [30]. PCR
products were cloned and forty-eight clones for each primer pair
were subsequently sequenced using the MegaBace system. As
described in [30], the sequence reads were base-called using
phred, clustered using phrap and aligned using ClustalW. The
number of generations between var gene sequencing and FACS/
IFA is indicated in Table 2.
Peptide Design
In order to investigate the involvement of the sequence motifs
found in the DBL1a domains of PfEMP1 from the Ugandan
isolates [30], we chose to design specific peptides, which were used
in subsequent experiments. Please see Fig. S2 for an alignment of
all included sequences. From the set of motifs we chose six motifs:
four motifs that were associated with severe malaria and belonged
to the groups defined in the Ugandan material as severe malaria 1
and 2 (S1S2), severe malaria 3/respiratory distress 5 (S3/R5, in
this manuscript named RDSM in order to avoid confusion with
the S3 domain of DBL1a [35]), high rosetting 1 and 2 (H1H2),
high rosetting 3 (H3), and two motifs that were associated with
mild disease and belonged to the low rosetting 1/mild malaria 4
(L1M4) and mild malaria 5 (M5) groups, respectively, see Fig. S1.
These motifs were chosen because of predicted surface availability
employing prediction program Phyre [53] and visualized by
PyMOL (The PyMOL Molecular Graphics System, Version 1.3,
Schro¨dinger, LLC). We further selected specific sequences from
the pool that represent each degenerate motif based on the
availability of in vitro adapted parasites predicted to express the
specific motif. From the choice of specific sequences representing
the motifs, we decided to extend the sequences in order to increase
the likelihood of mimicking the native secondary structures that
these motifs would have in the full-length protein. For this
purpose, we used the Phyre webserver [53] to model the 3D
structures of the DBL1a domains from which the sequences
originated. Most sequences were part of a-helical structures: we
therefore extended our selected sequences to include the full-
length predicted a-helices. The resulting sequences were used as
templates for the generation of peptides; the six different peptide
sequences (16 to 25 amino acids long) are listed in Table 1.
Tertiary Structure Modeling of NTS-DBL1a
The 3D structures of the NTS-DBL1a domains of R29 were
modeled using the Phyre2 server with intensive settings [53]. The
crystal structure of the NTS-DBL1a domain of Palo AltovarO
(Protein Data Bank accession code 2XUO) [42] was used as a
template and had the highest sequence and secondary structure
alignment score. Structural visualizations and high resolution
images were made using PyMOL.
Peptide Synthesis and Animal Immunization
An N-terminal cysteine was added to the peptides for
conjugation to KLH (keyhole limpet hemacyanin) and for
antibody affinity purification. The peptides were synthesized by
Innovagen (Lund, Sweden). We pre-screened animal sera by
Western blot using crude protein extracts of pRBCs and by IFA
techniques on dried monolayers of pRBC and excluded those that
showed pre-existing antibodies to the parasite or human red blood
cell proteins to avoid background staining in subsequent assays.
The selected animals (rats and rabbits) were immunized with
peptides coupled to KLH, emulsified in Freund’s complete (first
immunization) or incomplete adjuvant (second to fourth/fifth
immunization). The amount of peptide was 200 mg the first and
second immunizations and 100 mg the third, fourth and fifth
immunizations for both rats and rabbits. Animal immunizations
were carried out by Agrisera AB (Umea˚, Sweden).
Affinity Purification of Peptide Antibodies and Enzyme
Linked-immunosorbent Assay (ELISA)
Affinity purification of serum antibodies on the respective
peptide was done using UltraLink Iodoacetyl Matrix (Pierce,
Thermo Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions. In summary, affinity columns were
prepared by coupling 5 mg of each peptide to 2 ml of matrix for
45 min at room temperature (RT). After washes with five gel-bed
volumes of coupling buffer, the matrix was blocked by incubation
of L-cysteine-HCl for 45 min at RT. The sera were diluted 1:2
(rabbit) or 1:3 (rat) in PBS and were allowed to bind to the peptide
matrix for 1 hour at RT. The column was washed with five gel-
bed volumes of PBS (pH 7.4). The bound antibodies were eluted
with 0.1 M glycine-HCl (pH 2.5) and immediately neutralized
with 1 M Tris-HCl (pH 7.5). The antibody content of the eluted
fractions was measured by a Nanodrop spectrophotometer
(Thermo Scientific). The fractions containing antibodies were
pooled. Antibodies were subsequently dialyzed against PBS
pH 7.4 before they were stored in small aliquots at 220uC until
used.
Specificities and titers of the antibodies were confirmed by
ELISA; in short peptides were coated overnight at 4uC on
MaxiSorp plates (Nunc, Roskilde, Denmark) at a concentration of
4 mg/ml. All sera were added and titrated by serial dilutions of
1:121-1:161051 in PBS with 0.05% Tween (TPBS). The
antibodies were allowed to bind for two hours at RT and after
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three washes with TPBS, goat anti-rabbit total Ig and rabbit anti-
rat total Ig, both conjugated to HRP (horseradish peroxidase)
(DAKO, Glostrup, Denmark) were added at a concentrations of
1:8000 and 1:3500 respectively. After incubation for 30 min at RT
and subsequent washes, the reaction was developed with EC Blue
substrate system (Medicago AB, Uppsala, Sweden) and optical
density was read at 650 nm.
Immunofluorescence Assay on Dried pRBC and Live
Parasite Immunofluorescence Assays
Air-dried monolayers of trophozoite-pRBC of the parasites
FCR3S1.2, UAS22, UAS29, UKS111, R29 and 3D7AH1 were
prepared as previously described [54]. The monolayers were
blocked with 2% bovine serum albumin (BSA) in PBS and then
incubated with anti-peptide serum at dilutions 1:50, 1:100, 1:200,
1:400, 1:800 (rabbit sera) and 1:25, 1:50, 1:100, 1:200, 1:400 (rat
sera) and for affinity purified IgG 48, 24, 6 and 3 mg/ml,
respectively. The dilutions were in PBS and the antibodies were
allowed to bind for 60 min at RT. The slides were washed three
times in PBS and primary antibodies were detected with an
ALEXA488-conjugated goat anti-rat or goat anti-rabbit IgG
(Molecular Probes, Invitrogen, Carlsbad, CA, USA), diluted to
1:1000 for 60 min. All incubations were carried out at RT in a
humid chamber. Slides were mounted with Vectashield anti-
fading media containing DAPI for nuclear staining (Vector
Laboratories, Inc., Burlingame, CA, USA). The monolayers were
analyzed with 60x and 100x oil immersion lenses in a Nikon
Eclipse 80i microscope (Nikon Corporation, Japan). Pictures were
acquired with an Hamamatsu ORCA camera (Hamamatsu
Photonics System, Hamamatsu City, Japan) and analyzed with
ImageJ [55].
Flow Cytometry Assay on Parasitized Erythrocytes and
Live Cell Fluorescence Microscopy
The capacity of antibodies to bind to the surface of pRBC
parasitized by trophozoite stage parasites (24–30 hours post
merozoite invasion) was tested with flow cytometry as previously
described [51]. Briefly, the pRBCs were washed in PBS with 2%
FCS and then pre-incubated in the same medium for 30 min.
Subsequently, the cells were incubated with either serum (final
bleed or pre-bleed) in dilution 1:5 or with affinity purified IgG at a
concentration of 220 mg/ml for 30 min at RT. Non-immune rat/
rabbit IgG (Jackson ImmunoResearch Laboratories, Inc, West
Grove, PA, USA) were used as controls in the experiments with
affinity purified IgG at identical concentration. Subsequent to the
incubation with the primary antibody, the pRBCs were washed
thrice with FCS/PBS. After a 30 min incubation with a goat anti-
rat/rabbit IgG antibody coupled to ALEXA488 (dilution 1:100),
the pRBCs were washed thrice with FCS/PBS. Ethidium bromide
was added at a final concentration of 2.5 mg/ml after the last wash
and the pRBCs were resuspended in FCS/PBS after two
additional washes. The cell acquisition was done using flow
cytometry (FACSCalibur, BD Bioscience, Franklin Lakes, NJ
USA) where 5000 pRBCs were counted. The analysis was
performed using the FlowJo software (Tree Star, Inc. Ashland,
Oregon, USA). All assays were done in duplicates. Reactivity of
the pRBCs was scored as geometric mean fluorescence intensity as
described previously [56]. In order to compare the different FACS
acquisitions, the mean fluorescence of the pRBCs was calculated
with the following formula, taking into account the background
reactivity of unparasitized RBCs: (pRBCimmune/pRBCnon-immune)
– (RBCimmune/RBCnon-immune). This formula is less sensitive to
changes in the baseline voltage and thus less sensitive to changes in
the set up of the FACS instrument.
Peptide Array and Alanine Replacement Array
In order to map the antibody binding, specific peptide arrays
containing overlapping peptides were produced. The peptides
were bound chemoselectively to the microarray surface by
coupling an active amine (from the peptide) to an epoxy-group
(from the slide surface) by JPT Peptide Technologies, Berlin,
Germany. The peptides were 15 amino acids long with an 11
amino acids overlap. Each slide held three identical subarrays.
Array number one (Peptide array 1) held peptides corresponding
to five NTS-DBL1a-domains from the long-term cultivated
parasites FCR3S1.2var1, FCR3S1.2var2, R29, Palo AltovarO,
3D7var4 and three shorter DBL1a sequences from the Ugandan
isolates UAS22, UAS29 and UAS31 (Table S1A and B). To map
the essential amino acids required for antibody binding, an alanine
replacement array was produced in the same way (Peptide array 2).
The included peptides and the alanine replacements are shown in
Table S1C. Array number three (Peptide array 3) held peptides
containing 135 peptides covering the RDSM motif area. These
135 sequences were obtained from the 93 isolates obtained from
Ugandan children; a total of 241 sequences had been retrieved but
116 were duplicated in sequence as to the RDSM motif generating
135 unique sequences (Table S1D).
Assay procedure. The slides were incubated for 16 hours at
4uC in a humid chamber with rabbit- or rat affinity purified IgG
(5 mg/ml) or total rat serum (1:100) in PBS containing 3% of FCS
and 0.5% of Tween (TPBS). Five washing steps followed each
incubation step, two with TPBS, followed by three washing steps
with distilled water. All the solutions were sterile filtered using a
0.22 mm filter. The slides were then incubated with a 1:500
dilution of goat anti-rat- or goat anti-rabbit Cy5-conjugated
secondary antibodies (Jackson ImmunoResearch) for two hours at
RT in a humid chamber, followed by the five washing steps (see
above). The microarrays slides were scanned at wavelength of
635 nm using a GenePix 4000B microarray scanner (Axon
Instruments, Sunnyvale, CA, USA). The images were analyzed
using GenePixPro 7.0 software in combination with the.GAL file
provided by JPT. The mean of fluorescence intensity given by the
difference between the foreground and the local background were
used to measure the IgG response. The data represent the average
of the three subarrays. Anova test and Bonferroni post test were
applied to identify peptides that were differentially recognized by
the immunized animals compared to their controls (pre-immune
serum or purified non-immune IgG). The degenerate motifs were
generated using the WebLogo software [57].
Rosette Disruption Assay
Rosette disruption assays were performed on pRBC cultures of
trophozoites 20–24 hours post invasion as described elsewhere
[48]. Briefly, serum or IgG were added in dilutions 1:5 and 1:10 or
220 and 110 mg/ml in 40 ml of parasite culture, 5% hematocrit.
After incubating the samples at RT for 30 minutes the parasites
were stained with acridine orange and the rosettes were counted.
For each sample, 25 fields, equivalent to approximately 3500–
4000 RBCs, were counted. In parallel we also counted the
rosetting rate for control samples treated with non-immune rat/
rabbit serum or IgG at identical concentrations.
Supporting Information
Figure S1 Degenerate PfEMP1 sequence motifs. Shown
are the degenerated PfEMP1 motifs that were associated with
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severe malaria (S), mild malaria (M), high rosetting rate (H) or low
rosetting rate (L) in clinical isolates from Uganda (Normark et al,
PNAS 2007). Eight sequence motifs where chosen for immuniza-
tion depending on their predicted surface availability: H1, H2, H3,
S1, S2, S3, L1/M4, M5.
(PDF)
Figure S2 Alignment of included sequences. All DBL1a
sequences from the Normark paper (Normark et al, PNAS 2007)
are aligned to show how degenerate the RDSM motif is.
(PDF)
Figure S3 Indirect IFA on air-dried monolayers of the
clinical isolate UAS22. Specific donut pattern with rabbit anti-
DBL1a-RDSM antibodies (green) on a panel of parasite strains
and isolates. The parasite nucleus is stained with DAPI (blue).
(PDF)
Figure S4 Peptide array mapping rat anti-DBL1a-
RDSM antibody binding. A. Serum from rat 4. DBL1a
domains from UAS22 and R29. The rat 4 anti-DBL1a-RDSM
serum is shown in black and pre-immune serum is shown in grey.
The amino acid sequences are read from N- to C-terminal. The
amino acids included in the RDSM peptide are shown in bold
letters. B. Serum from rat 7. DBL1a domains from UAS22 and
R29. The rat anti-DBL1a-RDSM serum is shown in black and the
pre-immune serum is shown in grey. The amino acid sequences
are read from N- to C-terminal. The amino acids included in the
RDSM peptide are shown in bold letters.
(PDF)
Figure S5 Peptide array mapping the binding of rat
anti-DBL1a-RDSM IgG. The DBL1a domains assayed are
from FCR3S1.2var2, 3D7var4 and Palo AltovarO. The amino acid
sequences are read from N- to C-terminal. The rat anti-DBL1a-
RDSM IgG is shown in black and the non-immune rat IgG is
shown in grey. Statistically significant changes comparing rat anti-
DBL1a-RDSM IgG and non-immune rat IgG are marked with an
asterisk. * P,0.05.
(PDF)
Figure S6 Peptide array mapping the binding of rabbit
anti-DBL1a-RDSM IgG. The DBL1a domains assayed are
from FCR3S1.2var2, 3D7var4 and Palo AltovarO. The amino acid
sequences are read from N- to C-terminal. The rabbit anti-
DBL1a-RDSM IgG is shown in black and the non-immune rabbit
IgG is shown in grey. Statistically significant changes comparing
rabbit anti-DBL1a-RDSM IgG and non-immune rabbit IgG are
marked with an asterisk. * P,0.05.
(PDF)
Figure S7 Alanine replacement peptide array of the
DBL1a domains of parasites UAS22 and R29. Sera from rat
4 and 7 (final bleed) were run on the array. Rat 4 is shown in black
and rat 7 in grey. The reactivity is shown as a ratio between
modified and wild type sequence. Statistically significant changes
comparing pre-immune and immune sera are marked with an
asterisk, * P,0.05, **P,0.001.
(PDF)
Figure S8 Reactivity to 135 unique RDSM peptide
sequence. Rabbit and rat anti-DBL1a-RDSM IgG recognition
of 135 peptides covering the RDSM sequence motif. The peptide
sequences are shown in order of reactivity to rat anti-DBL1a-
RDSM IgG.
(PDF)
Table S1 Peptide sequences included in the microar-
rays.
(DOC)
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